# US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector

> **NCT04356339** · — · COMPLETED · sponsor: **Bayer** · enrollment: 100 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Interferon-beta-1b (BETASERON, BAY 86-5046)

## Key facts

- **NCT ID:** NCT04356339
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-24
- **Primary completion:** 2021-08-29
- **Final completion:** 2021-11-11
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04356339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04356339, "US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04356339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*